Scale-up, process validation, and technology transfer are conducted at the late phase of product development. However, the performance of these steps is largely dependent on the product composition and process selected in the early phase of development. The technology chosen at an early developmental stage and employed in manufacturing the bio-batch stays with it during its life. During this early phase, the development scientist must consider the future demand of the product in selecting the process and equipment. In reviewing a manufacturing process, it is important to consider the physico- chemical properties of the drug and excipients along with equipment capabilities and limitations. Involvement of production personnel in the manufacturing of a batch prior to the bio-batch often helps in the develop- ment of a robust process. All equipment should be quali¢ed for installation, operation, and performance prior to the bio-batch. The equipment should be cleaned and tested as per a cleaning validation protocol. The bio-batch should be evaluated for process performance as per a process validation protocol. All operational documents and test results generated from the bio-batch must be reviewed prior to initiating further scale-up and=or technology transfer. A team effort among formulation, validation, production, analytical, and logistic support groups is crucial to the success of scale-up and technology transfer.
Cite this article:
Yogita Chowdhary, Babita Kumar. SUPAC- Post Approval Changes suggested by FDA to Industry. Asian Journal of Research in Pharmaceutical Sciences. 2023; 13(1):29-2. doi: 10.52711/2231-5659.2023.00005
Yogita Chowdhary, Babita Kumar. SUPAC- Post Approval Changes suggested by FDA to Industry. Asian Journal of Research in Pharmaceutical Sciences. 2023; 13(1):29-2. doi: 10.52711/2231-5659.2023.00005 Available on: https://ajpsonline.com/AbstractView.aspx?PID=2023-13-1-5
1. Guidance for Industry.Changes to an Approved NDAor ANDA.USDepartment of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), November 1999, CMC.
2. Guidance for Industry. Immediate Release Solid Oral Dosage Forms—Scale-Up and Postapproval Changes: Chemistry, Manufacturing, and Controls, In Vitro Dissolution Testing, and In Vivo Bioequivalence Documentation. Center for Drug and Research (CDER), November 1995, CMC 5.
3. Guidance for Industry. SUPAC-IR=MR: Immediate Release and Modi¢ed Release Solid Oral Dosage Forms—Manufacturing Equipment Addendum. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), January 1999, CMC9 (Revision 1).
4. Guidance for Industry. Comparability Protocols—Chemistry, Manufacturing, and Controls Information. FDA, Center for Drug Evaluation and Research (CDER), February 2003, http://www.fda.gov=cder=guidance=5427dft.pdf.
5. O⁄ce of the Federal Register. 21 CFR 314.80. Revised as of April 1, 2002: 119^122.
6. Guidance for Industry. Postmarketing Adverse Experience Reporting for Human Drug and Licensed Biological Products: Clari¢cation of What to Report. Food and Drug Administration, August 1997.
7. Food and Drug Administration. MedWatch FDA Form 3500=3500A. http:==www.fda.gov=cder=guidance=5427dft.pdf, June 1993